
ADARx is the brand of ADARx Pharmaceuticals, Inc., the San Diego biotechnology company founded in 2019. The brand covers its next-generation siRNA therapeutic pipeline and delivery platform. The company listed on Nasdaq as ADRX on September 24, 2026.
Parent Company
Founded
2019
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| ADARx | ADARx Pharmaceuticals, Inc. | Wholly owned |
Zhen Li co-founded the company in December 2019 and became CEO in January 2020. The brand emerged from the San Diego biotech cluster with leadership drawn from Arrowhead Pharmaceuticals and Merck.
The brand's public identity formed around its siRNA delivery platform and a pipeline spanning multiple disease areas. The September 2026 Nasdaq listing made ADARx a public brand after six years of private development.
What does ADARx do?
ADARx develops siRNA therapeutics that silence disease-driving genes. Its pipeline targets cardiovascular, metabolic, complement, and neurological conditions using delivery technology that reaches tissues beyond the liver.
Is ADARx publicly traded?
Yes. ADARx listed on Nasdaq under ticker ADRX on September 24, 2026, raising approximately $446 million.
Who founded ADARx?
Zhen Li co-founded the company in December 2019 and serves as president and CEO. She previously led siRNA research at Arrowhead Pharmaceuticals and Merck.
Where is ADARx headquartered?
ADARx is headquartered at 5871 Oberlin Drive in San Diego, California.
Who owns ADARx?
After the IPO, ADARx is owned by public shareholders, founders, employees, and venture investors. AbbVie holds approximately 4.9% through an IPO investment capped at $100 million.
When did ADARx IPO?
ADARx priced its IPO on September 24, 2026, selling 26.25 million shares at $17 each for gross proceeds of approximately $446.3 million.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Amgen | USA | 1980 | Market leader | Global | All-ages | |
| Roche | USA | 1976 | Premium | Global | All-ages | |
| Lonza Group | Switzerland | 1897 | Mass market | Global | All Genders | |
| Regeneron | USA | 1988 | Premium | United states | All Genders |
Healthcare PharmaceuticalsOwned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
Healthcare PharmaceuticalsOwned by Roche
Genentech is a pioneering American biotechnology company and wholly owned member of the Roche Group, headquartered in South San Francisco, California.
Healthcare PharmaceuticalsOwned by Lonza Group Ltd
Swiss contract development and manufacturing organization serving pharmaceutical, biotech, and nutrition markets, founded in 1897 in the Valais Alps.
Healthcare PharmaceuticalsOwned by Regeneron Pharmaceuticals, Inc.
Biotechnology brand of Regeneron Pharmaceuticals, developer of Eylea, Dupixent, and Libtayo, headquartered in Tarrytown, New York.
Market Positioning: ADARx competes with 4 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by ADARx Pharmaceuticals, Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
Boehringer Ingelheim is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Herbion Pakistan Private Limited
Pakistani natural healthcare company founded in 1983, exporting 250+ herbal, nutraceutical, and personal care products to more than 40 countries.
Herbion is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
Jardiance is privately owned, unlike ADARx which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike ADARx which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.